Eddie Hickman
Stock Analyst at Guggenheim
(4.59)
# 934
Out of 5,028 analysts
47
Total ratings
65.2%
Success rate
30.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Reiterated: Buy | $69 → $100 | $9.37 | +967.24% | 8 | Aug 14, 2026 | |
| GHRS GH Research | Reiterated: Buy | $34 → $40 | $22.17 | +80.42% | 5 | Aug 6, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $24 → $23 | $10.70 | +114.95% | 9 | Aug 6, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $90 → $89 | $74.46 | +19.54% | 16 | Jul 21, 2026 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $0.5955 | n/a | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $33.25 | n/a | 2 | Aug 11, 2025 |
ProMIS Neurosciences
Aug 14, 2026
Reiterated: Buy
Price Target: $69 → $100
Current: $9.37
Upside: +967.24%
GH Research
Aug 6, 2026
Reiterated: Buy
Price Target: $34 → $40
Current: $22.17
Upside: +80.42%
Zevra Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $24 → $23
Current: $10.70
Upside: +114.95%
Tarsus Pharmaceuticals
Jul 21, 2026
Reiterated: Buy
Price Target: $90 → $89
Current: $74.46
Upside: +19.54%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.5955
Upside: n/a
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $33.25
Upside: n/a